KEW
Founded Year
2011Stage
Series C | AliveTotal Raised
$32.87MMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+206 points in the past 30 days
About KEW
KEW is a comprehensive genomic profiling company operating in the healthcare sector. The company's main service is providing therapeutic options for cancer care based on an individual patient's tumor genetic profile. KEW primarily sells to the healthcare industry, specifically molecular labs and physicians. KEW was formerly known as KEW Group. It was founded in 2011 and is based in Cambridge, Massachusetts.
Loading...
Loading...
Latest KEW News
Sep 19, 2024
His credentials include 21 years at Warburg Pincus Share Global specialty (re)insurance firm Ascot Group has picked Kewsong Lee (pictured), founder and chief executive of BellTower Partners, as its new board chairman. Lee is replacing executive chair Neill Currie, who will transition into the role of independent director. The business leader brings over 30 years of leadership and strategic expertise to the post, having helmed various high-profile global organisations. His recent venture, private holding company BellTower Partners, invests permanent capital in private enterprises. Lee’s extensive background in the insurance sector includes his tenure as a board member at RenaissanceRe Holdings and Arch Capital. He was also in charge of the acquisition and growth of Fortitude Re during his time as CEO of The Carlyle Group from 2018 to 2022. Ascot group president and CEO Jonathan Zaffino welcomed Lee to the board, stating: “Kew’s appointment as chairman complements the existing skillsets represented on our board, and we look forward to benefitting from his additional guidance as a proven leader with a track record of success in the financial and insurance industry. “As Ascot continues to scale its global platform and expand its ecosystem of talented underwriters, we are confident that Kew’s contributions and unique skills will be highly accretive to Ascot as we continue on the company’s growth trajectory.” Currie also had nothing but nice words for his successor: “Having known Kew for over 30 years, since the formation of RenaissanceRe in 1993, I am certain that having an executive of his calibre join the board will position the business for continued success as we build on the strong momentum that our talented management team has set in motion.” As part of Lee’s new position, BellTower Partners will make a minority investment in Ascot to support the company’s continued growth and strategic objectives. Canada Pension Plan Investment Board (CPP Investments), meanwhile, will continue to hold the majority ownership in Ascot. CPP Investments managing director and Ascot board director Sam Blaichman, who thanked Currie for his contributions, commented: “We look forward to working with Kew and BellTower in this next chapter in Ascot’s growth journey, as the management team continues to develop solutions to help clients navigate today’s challenging risk landscape.” Meanwhile Lee, who was at Warburg Pincus for 21 years, had this to say: “As a global participant in the insurance and reinsurance industries, Ascot is consistently achieving strong results, and I look forward to working with Jonathan and his talented team to continue scaling the business as we focus on long-term, sustainable growth and return on capital. “BellTower believes there is tremendous opportunity ahead for Ascot , and I am excited to partner with CPP Investments and management to help drive significant value creation.” What do you think about this story? Share your thoughts in the comments below. Fetching comments...
KEW Frequently Asked Questions (FAQ)
When was KEW founded?
KEW was founded in 2011.
Where is KEW's headquarters?
KEW's headquarters is located at 840 Memorial Drive, 4th Floor, Cambridge.
What is KEW's latest funding round?
KEW's latest funding round is Series C.
How much did KEW raise?
KEW raised a total of $32.87M.
Who are the investors of KEW?
Investors of KEW include The Bolyston Street Group, Signet Healthcare Partners, Amzak Capital Management, Arsenal Capital Management and Cardinal Health.
Who are KEW's competitors?
Competitors of KEW include Perthera.
Loading...
Compare KEW to Competitors
CureMatch is a healthcare technology company specializing in precision oncology and digital decision support solutions for cancer treatment. The company offers services that analyze genomic biomarkers to match patients with personalized cancer treatments, utilizing AI algorithms to rank combination therapy options. CureMatch primarily serves oncologists and cancer treatment centers seeking to implement precision medicine strategies. It was founded in 2015 and is based in San Diego, California.
Caris focuses on molecular science, specifically in the domain of cancer care. The company offers services such as molecular profiling, blood profiling, and tissue profiling, which provide comprehensive molecular information to help oncologists create personalized treatment plans for cancer patients. It primarily sells to the healthcare industry, particularly oncology. It was founded in 1996 and is based in Irving, Texas.
Massive Bio operates as an Artificial intelligence (AI) driven platform specializing in personalized oncology solutions within the healthcare sector. The company offers services that connect cancer patients and oncologists to clinical trials for new, alternative, and targeted treatments, as well as providing personalized treatment recommendations through a virtual tumor board. It primarily serves the healthcare industry, particularly oncology care providers and cancer patients seeking treatment options. It was founded in 2014 and is based in New York.
Clarified Precision Medicine provides actionable treatment recommendations in the precision medicine sector, focusing on oncology. It offers treatment guidance, disease monitoring, and early cancer detection services, all informed by the molecular features of individual patients' tumors. It serves the healthcare industry, particularly oncologists and cancer care providers. It was founded in 2020 and is based in Tampa, Florida.
Perthera operates as a healthcare artificial intelligence company focusing on advancing precision medicine. The company offers an artificial intelligence (AI) enabled platform utilizing patient history and multi-omic testing results to match cancer patients with ranked therapy options, and accelerates clinical and therapeutic innovation. It was formerly known as Personalized Cancer Therapy. It primarily serves the healthcare industry in the oncology sector. It was founded in 2012 and is based in McLean, Virginia.
NeoGenomics Laboratories is a company focused on cancer diagnostics within the healthcare sector. The company offers a range of diagnostic services including cancer cytogenetics, hematologic and solid tumor FISH testing, flow cytometry, and molecular oncology tests. These services are primarily aimed at the healthcare industry, including hospital and private pathology laboratories, office-based oncologists, and academic institutions. It was founded in 2001 and is based in Fort Myers, Florida.
Loading...